Expression of CK-19 and CEA mRNA in peripheral blood of gastric cancer patients

dc.citation.epage268en_US
dc.citation.issueNumber4en_US
dc.citation.spage263en_US
dc.citation.volumeNumber32en_US
dc.contributor.authorKutun, S.en_US
dc.contributor.authorCelik, A.en_US
dc.contributor.authorCem Kockar, M.en_US
dc.contributor.authorErkorkmaz, U.en_US
dc.contributor.authorEroǧlu, A.en_US
dc.contributor.authorCetin, A.en_US
dc.contributor.authorErkosar, B.en_US
dc.contributor.authorYakicier, C.en_US
dc.date.accessioned2016-02-08T09:55:14Z
dc.date.available2016-02-08T09:55:14Z
dc.date.issued2010en_US
dc.departmentDepartment of Molecular Biology and Geneticsen_US
dc.description.abstractAim: To investigate the clinical and pathological relevance of detection of circulating tumor cells (CTC) in the peripheral blood of gastric carcinoma patients before operation. Patients and Methods: Fifty patients with gastric adenocarcinoma were analysed prospectively. Patients were divided into two groups according to the extent of the tumor. Group I (unresectable) consisted of 22, and group II (resectable) consisted of 28 patients. Peripheral blood samples were collected pre-operatively from all 50 patients as well as from ten healthy controls and analyzed for carcinoembryonic antigen (CEA) and cytokeratin-19 (CK-19) messenger ribonucleic acids (mRNAs). Tumor localisation, stage, presence of signet cell formation, nodal metastases, serousal and lymphovascular invasion were recorded for all patients. Results: Expression of CK-19 was detected in 24 (48%), and CEA in 10 (20%) cases. Nine patients (40%) in group I and 15 (53.6%) in group II were positive for CK-19 expression. CEA expression was more frequent among group I patients (6 vs. 4 cases). There was no significant difference between the groups in the expression of CK-19 and CEA mRNA, tumor localisation, presence of signet formation, and presence and extent of nodal metastases. Patients with major vascular invasion (MVI) expressed significantly higher levels of CTC mRNA compared to those without MVI (p = 0.023 for CEA, and p = 0.009 for CK-19). The median 1 and 2-year survival was 9.5 and 10.5 months for group I, and 20 and 28.5 months for group II, respectively (p = 0.001). The mean survival was 6.7 months for patients with MVI, and 30.2 months for those without MVI (p = 0.0001). Conclusions: High levels of CTCs were observed in patients with MVI invasion, rather than other causes of unresectability. It can be suggested that expression of both CEA and CK-19 in the peripheral blood of gastric cancer patients are strong predictors of MVI and significantly worse survival rates. Copyright © Experimental Oncology, 2010.en_US
dc.description.provenanceMade available in DSpace on 2016-02-08T09:55:14Z (GMT). No. of bitstreams: 1 bilkent-research-paper.pdf: 70227 bytes, checksum: 26e812c6f5156f83f0e77b261a471b5a (MD5) Previous issue date: 2010en
dc.identifier.issn18129269
dc.identifier.urihttp://hdl.handle.net/11693/22085
dc.language.isoEnglishen_US
dc.source.titleExperimental Oncologyen_US
dc.subjectCarcinoembryonic antigenen_US
dc.subjectCytokeratin-19en_US
dc.subjectGastric carcinomaen_US
dc.subjectMicrometastasesen_US
dc.subjectmRNAen_US
dc.subjectVascular invasionen_US
dc.subjectcarcinoembryonic antigenen_US
dc.subjectcytokeratin 19en_US
dc.subjectfluorouracilen_US
dc.subjectfolinic aciden_US
dc.subjectmessenger RNAen_US
dc.subjectadulten_US
dc.subjectageden_US
dc.subjectantigen expressionen_US
dc.subjectarticleen_US
dc.subjectcancer invasionen_US
dc.subjectcancer localizationen_US
dc.subjectcancer patienten_US
dc.subjectcancer surgeryen_US
dc.subjectcancer survivalen_US
dc.subjectcellen_US
dc.subjectcontrolled studyen_US
dc.subjectdisease severityen_US
dc.subjectfemaleen_US
dc.subjecthumanen_US
dc.subjecthuman cellen_US
dc.subjecthuman tissueen_US
dc.subjectlymph node metastasisen_US
dc.subjectlymph vesselen_US
dc.subjectmajor clinical studyen_US
dc.subjectmaleen_US
dc.subjectmetastasisen_US
dc.subjectmultiple cycle treatmenten_US
dc.subjectpredictor variableen_US
dc.subjectprospective studyen_US
dc.subjectsignet cellen_US
dc.subjectstomach adenocarcinomaen_US
dc.subjectstomach carcinomaen_US
dc.subjectsurvival rateen_US
dc.subjectsurvival timeen_US
dc.subjecttumor cellen_US
dc.subjecttumor localizationen_US
dc.subjectAdenocarcinomaen_US
dc.subjectAdulten_US
dc.subjectAgeden_US
dc.subjectAged, 80 and overen_US
dc.subjectCarcinoembryonic Antigenen_US
dc.subjectFemaleen_US
dc.subjectHumansen_US
dc.subjectKaplan-Meier Estimateen_US
dc.subjectKeratin-19en_US
dc.subjectMaleen_US
dc.subjectMiddle Ageden_US
dc.subjectNeoplastic Cells, Circulatingen_US
dc.subjectPrognosisen_US
dc.subjectReverse Transcriptase Polymerase Chain Reactionen_US
dc.subjectRNA, Messengeren_US
dc.subjectStomach Neoplasmsen_US
dc.subjectTumor Markers, Biologicalen_US
dc.titleExpression of CK-19 and CEA mRNA in peripheral blood of gastric cancer patientsen_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Expression of CK-19 and CEA mRNA in peripheral blood of gastric cancer patients.pdf
Size:
134.76 KB
Format:
Adobe Portable Document Format
Description:
Full printable version